Céline Desvignes

545 total citations
26 papers, 292 citations indexed

About

Céline Desvignes is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Immunology. According to data from OpenAlex, Céline Desvignes has authored 26 papers receiving a total of 292 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Radiology, Nuclear Medicine and Imaging, 11 papers in Oncology and 11 papers in Immunology. Recurrent topics in Céline Desvignes's work include Monoclonal and Polyclonal Antibodies Research (10 papers), Biosimilars and Bioanalytical Methods (6 papers) and Colorectal Cancer Treatments and Studies (5 papers). Céline Desvignes is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (10 papers), Biosimilars and Bioanalytical Methods (6 papers) and Colorectal Cancer Treatments and Studies (5 papers). Céline Desvignes collaborates with scholars based in France, United Kingdom and United States. Céline Desvignes's co-authors include Gilles Paintaud, Christophe Passot, David Ternant, Denis Mulleman, Hervé Watier, Véronique Dièras, Olivier Trédan, F. Mefti, Patricia Tresca and Claire Bonneau and has published in prestigious journals such as The Journal of Immunology, Cancer Research and International Journal of Molecular Sciences.

In The Last Decade

Céline Desvignes

25 papers receiving 288 citations

Peers

Céline Desvignes
L Pan United Kingdom
Bernard Lauwerys Belgium
Monica Concardi Italy
Rintaro Ohe Japan
Paula Estrada Spain
Lena Liu United States
Steve Abella United States
Chelsea C. Estrada United States
Léna Absi France
Aiysha Abid Pakistan
L Pan United Kingdom
Céline Desvignes
Citations per year, relative to Céline Desvignes Céline Desvignes (= 1×) peers L Pan

Countries citing papers authored by Céline Desvignes

Since Specialization
Citations

This map shows the geographic impact of Céline Desvignes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Céline Desvignes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Céline Desvignes more than expected).

Fields of papers citing papers by Céline Desvignes

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Céline Desvignes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Céline Desvignes. The network helps show where Céline Desvignes may publish in the future.

Co-authorship network of co-authors of Céline Desvignes

This figure shows the co-authorship network connecting the top 25 collaborators of Céline Desvignes. A scholar is included among the top collaborators of Céline Desvignes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Céline Desvignes. Céline Desvignes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bluett, James, Floris C. Loeff, Mehmet İtik, et al.. (2025). Quality Assessment of Therapeutic Drug Monitoring Assays of Therapeutic Antibodies Across Europe: An Update. Basic & Clinical Pharmacology & Toxicology. 137(5). e70129–e70129.
2.
Gatault, Philippe, Rébecca Sberro‐Soussan, Christophe Passot, et al.. (2024). Eculizumab dose tapering should take into account the nonlinearity of its pharmacokinetics. British Journal of Clinical Pharmacology. 90(5). 1312–1321. 1 indexed citations
3.
Paintaud, Gilles, Nicolas Azzopardi, Christophe Passot, et al.. (2023). Relationship Between Cetuximab Target-Mediated Pharmacokinetics and Progression-Free Survival in Metastatic Colorectal Cancer Patients. Clinical Pharmacokinetics. 62(9). 1263–1274. 1 indexed citations
4.
Caulet, Morgane, Gilles Paintaud, Nicolas Azzopardi, et al.. (2023). Confounding mitigation for the exposure‐response relationship of bevacizumab in colorectal cancer patients. British Journal of Clinical Pharmacology. 90(4). 976–986. 1 indexed citations
5.
Desvignes, Céline, David Ternant, Thierry Lecomte, et al.. (2021). A Robust Enzyme-Linked Immunosorbent Assay to Measure Serum Ramucirumab Concentrations. Bioanalysis. 13(7). 565–574. 2 indexed citations
6.
Petitcollin, Antoine, Nicolas Azzopardi, Jean‐Yves Pierga, et al.. (2021). Population pharmacokinetics and exposure–response relationship of trastuzumab and bevacizumab in early-stage breast cancer. European Journal of Clinical Pharmacology. 77(12). 1861–1873. 5 indexed citations
7.
Cartron, Guillaume, Ulrich Specks, Denis Mulleman, et al.. (2021). The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target-Mediated Drug Disposition. Clinical Pharmacokinetics. 61(3). 423–437. 9 indexed citations
8.
Azzopardi, Nicolas, Claire Bonneau, Céline Desvignes, et al.. (2021). Antigen Mass May Influence Trastuzumab Concentrations in Cerebrospinal Fluid After Intrathecal Administration. Clinical Pharmacology & Therapeutics. 110(1). 210–219. 7 indexed citations
9.
Corset, Laetitia, Céline Desvignes, Gilles Paintaud, et al.. (2021). Panitumumab and Cetuximab Affect Differently Mirna Expression in Colorectal Cancer Cells. Biomarkers in Medicine. 15(10). 685–696. 4 indexed citations
10.
Nguyen, Thuy Thanh, Quang Nguyen, Céline Desvignes, et al.. (2019). A successful compartmental approach for the treatment of breast cancer brain metastases. Cancer Chemotherapy and Pharmacology. 83(3). 573–580. 2 indexed citations
11.
Bonneau, Claire, Gilles Paintaud, Olivier Trédan, et al.. (2018). Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis. European Journal of Cancer. 95. 75–84. 66 indexed citations
12.
Desvignes, Céline, Christophe Passot, David Ternant, et al.. (2018). Development and Validation of an ELISA to Study Panitumumab Pharmacokinetics. Bioanalysis. 10(4). 205–214. 4 indexed citations
13.
Ternant, David, Christophe Passot, Alexandre Aubourg, et al.. (2017). Model-Based Therapeutic Drug Monitoring of Infliximab Using a Single Serum Trough Concentration. Clinical Pharmacokinetics. 57(9). 1173–1184. 15 indexed citations
14.
Bian, Sumin, Céline Desvignes, Céline Bris, et al.. (2017). Immunoassays for Measuring Serum Concentrations of Monoclonal Antibodies and Anti-biopharmaceutical Antibodies in Patients. Therapeutic Drug Monitoring. 39(4). 316–321. 19 indexed citations
15.
Passot, Christophe, Céline Desvignes, David Ternant, et al.. (2017). Development and Validation of an Enzyme-Linked Immunosorbent Assay to Measure Free Eculizumab Concentration in Serum. Bioanalysis. 9(16). 1227–1235. 10 indexed citations
16.
Arnoult, Christophe, Guillaume Brachet, Nicolas Azzopardi, et al.. (2017). Crucial Role for Immune Complexes but Not FcRn in Immunization against Anti–TNF-α Antibodies after a Single Injection in Mice. The Journal of Immunology. 199(2). 418–424. 18 indexed citations
17.
Benhamou, Y., Gilles Paintaud, Élie Azoulay, et al.. (2016). Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: Results of a phase II, multicenter noncomparative study. American Journal of Hematology. 91(12). 1246–1251. 39 indexed citations
18.
Desvignes, Céline, et al.. (2015). Development and Validation of an Enzyme-Linked Immunosorbent Assay to Measure Adalimumab Concentration. Bioanalysis. 7(10). 1253–1260. 15 indexed citations
19.
20.
Baas, Jara M., et al.. (2014). Pharmacokinetics and safety of cetuximab in a patient with renal dysfunction. Cancer Chemotherapy and Pharmacology. 73(6). 1303–1306. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by L Pan Breakdown of academic impact, for papers by Bernard Lauwerys Breakdown of academic impact, for papers by Monica Concardi Breakdown of academic impact, for papers by Rintaro Ohe Breakdown of academic impact, for papers by Paula Estrada Breakdown of academic impact, for papers by Lena Liu Breakdown of academic impact, for papers by Steve Abella Breakdown of academic impact, for papers by Chelsea C. Estrada Breakdown of academic impact, for papers by Léna Absi Breakdown of academic impact, for papers by Aiysha Abid
Rankless by CCL
2026